Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, “Company”, “GTG”)) is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment.
Highlights:
• GeneType outperforms 5-year and remaining lifetime risk prediction compared to the commonly used clinical models Gail and IBISv7, respectively.
• The study results provide further clinical validation for the breast cancer risk score component of recently announced Comprehensive Breast and Ovarian HBOC Risk Test.
• The study highlighted geneType’s ability, when using United States clinical guidelines,1 to identify more women for whom chemoprevention or increased screening would improve outcomes.
• GeneType and the more complex Rosner model had similar performance, with geneType’s data collection simplicity making its adoption in general practice easier.
• If women with stage 2 and above breast cancer had been assessed with geneType they could have been diagnosed with earlier stage cancer, with the corresponding prognostic improvements.
• The use of geneType could improve uptake of risk-reducing medication, potentially resulting in a significant reduction in the incidence of breast cancer.
The paper reports results from an extensive study undertaken by the GTG Scientific Team in collaboration with eminent researchers from Harvard Medical School (United States) and the University of Melbourne (Australia). The study compared geneType’s simple breast cancer risk assessment against a complex model with more risk factors and two commonly used clinical models (Gail and IBIS). GeneType outperformed both the Gail and IBIS models by a significant margin and had equivalent performance to the Rosner model without the need to collect a substantially larger number of risk factors.